Company research
CODEXIS, INC.
CIK 1200375Updated Nov 13, 2026
SecurityCDXS · NASDAQ · equity
Name history
CODEXIS INC · through Jun 13, 2019
CDXS price & chart
Loading TradingView…
NASDAQ:CDXS on TradingView ↗About the company
Codexis® is a leading provider of high-performance enzymatic solutions for efficient and scalable therapeutics manufacturing. The company is currently developing its proprietary ECO Synthesis® Manufacturing Platform, an aqueous enzymatic process that may offer a scalable alternative to traditional solid phase organic synthesis of oligonucleotide manufacturing. Initially, Codexis is applying its technology to address the rapidly growing demand for RNAi therapeutics. Codexis’ unique enzymes can drive improvements such as higher yields, increased purity, reduced energy usage and waste generation, stereoisomer control of siRNA, and improved overall capacity in manufacturing at substantially lower capital requirements, all of which may lead to greater efficiency and reduced costs. In addition, the company supplies high-performance enzymes through its BioCatalysis business that are used in the manufacture of multiple commercially available small molecule therapeutics. For additional information, please visit https://www.codexis.com.
In the news
Codexis Announces Pricing of Public Offering of Common Stock ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities
Items 1.01, 1.02, 2.03, 3.02, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 123,961,000Source | 148,183,000Source | 120,055,000Source | 138,246,000Source | 132,006,000Source | 129,370,000Source | 128,887,000Source | 149,559,000Source | 147,797,000Source | 149,011,000Source | 136,561,000Source | 250,393,000Source |
| Property, Plant and Equipment, NetUSD | 14,012,000Source | 13,266,000Source | 11,907,000Source | 14,984,000Source | 13,966,000Source | 12,588,000Source | 15,803,000Source | 14,668,000Source | 13,024,000Source | 14,197,000Source | 15,487,000Source | 22,614,000Source |
| GoodwillUSD | 2,463,000Source | 2,463,000Source | 2,463,000Source | 2,463,000Source | 2,463,000Source | 2,463,000Source | 2,463,000Source | 2,463,000Source | 2,463,000Source | 2,463,000Source | 2,463,000Source | 3,241,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 25,351,000Source | 37,452,000Source | 27,172,000Source | 26,761,000Source | 18,595,000Source | 36,571,000Source | 18,319,000Source | 58,046,000Source | 50,793,000Source | 19,264,000Source | 65,116,000Source | 113,984,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | — | — | — | — | — | — | — | 10,036,000Source | 31,904,000Source |
| Inventory, NetUSD | 1,936,000Source | 2,103,000Source | 1,602,000Source | 1,945,000Source | 2,232,000Source | 2,000,000Source | 1,781,000Source | 2,441,000Source | 1,817,000Source | 1,799,000Source | 2,685,000Source | 2,029,000Source |
| Assets, CurrentUSD | 76,192,000Source | 112,902,000Source | 71,916,000Source | 88,729,000Source | 91,398,000Source | 79,649,000Source | 77,808,000Source | 107,948,000Source | 96,816,000Source | 98,772,000Source | 93,466,000Source | 162,894,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,337,000Source | 3,490,000Source | 3,327,000Source | 3,469,000Source | 3,062,000Source | 4,057,000Source | 4,155,000Source | 5,269,000Source | 5,626,000Source | 4,128,000Source | 5,218,000Source | 5,487,000Source |
| Operating Lease, Right-of-Use AssetUSD | 26,522,000Source | 10,772,000Source | 28,618,000Source | 27,260,000Source | 11,576,000Source | 29,566,000Source | 27,986,000Source | 12,364,000Source | 30,501,000Source | 28,700,000Source | 13,137,000Source | 39,263,000Source |
| Other Assets, NoncurrentUSD | 912,000Source | 1,928,000Source | 1,041,000Source | 950,000Source | 1,841,000Source | 994,000Source | 967,000Source | 1,354,000Source | 883,000Source | 1,019,000Source | 1,246,000Source | 350,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 85,417,000Source | 74,783,000Source | 87,097,000Source | 82,615,000Source | 70,559,000Source | 86,136,000Source | 79,258,000Source | 70,292,000Source | 97,268,000Source | 82,084,000Source | 49,946,000Source | 105,596,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 9,000Source | 8,000Source | 9,000Source | 9,000Source | 7,000Source | 9,000Source | 8,000Source | 7,000Source | 9,000Source | 8,000Source | 7,000Source | 6,000Source |
| Additional Paid in CapitalUSD | 654,904,000Source | 625,696,000Source | 660,451,000Source | 652,391,000Source | 593,253,000Source | 658,720,000Source | 633,101,000Source | 588,311,000Source | 657,292,000Source | 629,673,000Source | 584,138,000Source | 566,081,000Source |
| Retained Earnings (Accumulated Deficit)USD | -616,381,000Source | -552,430,000Source | -627,489,000Source | -596,766,000Source | -531,790,000Source | -615,484,000Source | -583,494,000Source | -509,035,000Source | -606,780,000Source | -562,806,000Source | -497,530,000Source | -421,290,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 12,000Source | 126,000Source | -13,000Source | -3,000Source | -23,000Source | -11,000Source | 14,000Source | -16,000Source | 8,000Source | 52,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 38,544,000Source | 73,400,000Source | 32,958,000Source | 55,631,000Source | 61,447,000Source | 43,234,000Source | 49,629,000Source | 79,267,000Source | 50,529,000Source | 66,927,000Source | 86,615,000Source | 144,797,000Source |
| Liabilities and EquityUSD | 123,961,000Source | 148,183,000Source | 120,055,000Source | 138,246,000Source | 132,006,000Source | 129,370,000Source | 128,887,000Source | 149,559,000Source | 147,797,000Source | 149,011,000Source | 136,561,000Source | 250,393,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 18,475,000Source | 35,129,000Source | 23,511,000Source | 15,237,000Source | 30,539,000Source | 14,850,000Source | 20,901,000Source | 29,080,000Source | 25,317,000Source | 23,648,000Source | 35,830,000Source | 49,066,000Source |
| Operating Lease, Liability, CurrentUSD | 3,091,000Source | 4,081,000Source | 3,294,000Source | 3,001,000Source | 3,979,000Source | 3,302,000Source | 2,913,000Source | 3,879,000Source | 2,944,000Source | 2,827,000Source | 10,121,000Source | 5,360,000Source |
| Accounts Payable, CurrentUSD | 2,425,000Source | 4,212,000Source | 2,609,000Source | 1,468,000Source | 3,685,000Source | 2,127,000Source | 6,046,000Source | 3,465,000Source | 1,554,000Source | 2,838,000Source | 5,947,000Source | 3,246,000Source |
| Operating Lease, Liability, NoncurrentUSD | 25,801,000Source | 9,134,000Source | 28,417,000Source | 26,606,000Source | 10,191,000Source | 29,118,000Source | 27,398,000Source | 11,232,000Source | 30,159,000Source | 28,163,000Source | 12,243,000Source | 38,278,000Source |
| Other Liabilities, NoncurrentUSD | 1,312,000Source | 1,279,000Source | 1,350,000Source | 1,299,000Source | 1,264,000Source | 1,335,000Source | 1,283,000Source | 1,248,000Source | 1,327,000Source | 1,268,000Source | 1,233,000Source | 1,371,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 2,987,000Source | 6,505,000Source | 3,365,000Source | 3,406,000Source | 5,417,000Source | 3,196,000Source | 5,117,000Source | 5,374,000Source | 2,768,000Source | 6,223,000Source | 4,735,000Source | 15,279,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 58,701,000Source | 90,300,000Source | 54,918,000Source | 66,330,000Source | 73,200,000Source | 65,140,000Source | 59,800,000Source | 85,500,000Source | 78,209,000Source | 73,458,000Source | — | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 11,000Source | 14,000Source | 16,000Source | 16,000Source |
| Long-term DebtUSD | 39,729,000Source | 28,631,000Source | 40,876,000Source | 39,373,000Source | 28,365,000Source | 40,483,000Source | 29,186,000Source | 28,102,000Source | 40,105,000Source | 28,905,000Source | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 39,729,000Source | 28,631,000Source | 33,819,000Source | 39,373,000Source | 28,365,000Source | 40,483,000Source | 29,186,000Source | 28,102,000Source | 40,105,000Source | 28,905,000Source | — | — |
| Short-term InvestmentsUSD | 33,350,000Source | 52,800,000Source | 27,746,000Source | 39,569,000Source | 54,600,000Source | 28,569,000Source | 41,500,000Source | 27,500,000Source | 27,416,000Source | 54,194,000Source | — | — |
| Long-term Debt, Current Maturities | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 1,286,000Source | 1,195,000Source | 5,248,000Source | 4,946,000Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 2,513,000Source | 2,708,000Source | 1,583,000Source | 2,532,000Source | 1,428,000Source | 2,379,000Source | 9,624,000Source | 13,087,000Source | 9,971,000Source | 14,531,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 183,000Source | -18,000Source | 19,000Source | -886,000Source | 656,000Source | 869,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 312,000Source | 2,065,000Source | -1,286,000Source | -2,567,000Source | 2,287,000Source | 207,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -3,000Source | -2,000Source | 0Source | -7,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -13,150,000Source | -13,798,000Source | -19,376,000Source | -49,410,000Source | -52,638,000Source | 11,284,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -1,111,000Source | 11,769,000Source | 23,502,000Source | -56,980,000Source | -4,858,000Source | -13,578,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 176,000Source | 1,255,000Source | 4,471,000Source | 4,305,000Source | 4,418,000Source | 8,307,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 404,000Source | 1,488,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -14,000Source | 1,085,000Source | 27,928,000Source | 60,522,000Source | 8,167,000Source | -575,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -14,275,000Source | -944,000Source | 32,054,000Source | -45,868,000Source | -49,329,000Source | -2,869,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 26,898,000Source | 39,028,000Source | 29,206,000Source | 28,325,000Source | 38,608,000Source | 19,885,000Source | 52,883,000Source | 20,829,000Source | 66,697,000Source | 116,026,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 892,000Source | 432,000Source | 3,149,000Source | 2,566,000Source | 44,000Source | 34,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | 0Source | — | 17,000Source | 194,000Source | 100,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | 700,000Source | 2,000,000Source | 1,000,000Source | 1,000,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | 376,000Source | 281,000Source | 1,305,000Source | 885,000Source | — | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 58,701,000Source | 90,300,000Source | 54,918,000Source | 66,330,000Source | 65,140,000Source | 59,800,000Source | 78,209,000Source | 73,458,000Source | — | — |
| Debt and Equity Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | — | 208,000Source |
| DepreciationUSD | — | — | 1,318,000Source | 1,184,000Source | 1,198,000Source | 1,302,000Source | 1,248,000Source | 1,158,000Source | 5,097,000Source | 4,845,000Source | 5,518,000Source | 5,402,000Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | — |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | — | — | — | 3,900,000Source | — | — | — | — | 300,000Source | 6,902,000Source | 12,215,000Source | — |
| GoodwillUSD | — | — | 2,463,000Source | 2,463,000Source | 2,463,000Source | 2,463,000Source | 2,463,000Source | 2,463,000Source | 2,463,000Source | 2,463,000Source | 2,463,000Source | 3,241,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | 0Source | 778,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | 8,000Source | 10,000Source | 10,000Source | 10,000Source | 36,000Source | 11,000Source | 47,000Source | 34,000Source | 69,000Source | 276,000Source |
| Investment Income, InterestUSD | — | — | 634,000Source | 849,000Source | 535,000Source | 584,000Source | 665,000Source | 751,000Source | 2,625,000Source | 3,670,000Source | 4,172,000Source | 1,441,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -19,615,000Source | -20,640,000Source | -12,005,000Source | -13,272,000Source | -8,704,000Source | -20,688,000Source | -43,974,000Source | -65,276,000Source | -76,240,000Source | -33,592,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | 2,997,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | -1,292,000Source | -4,922,000Source | -1,301,000Source | -984,000Source | -1,290,000Source | -942,000Source | -4,813,000Source | -10,393,000Source | -12,274,000Source | 124,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | — | — | 503,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 17,267,000Source | 31,319,000Source | 8,652,000Source | 0Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | 0Source | 9,897,000Source | 29,521,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 0Source | 1,098,000Source | 1,098,000Source | 1,384,000Source | 422,000Source | 955,000Source |
| Financing Receivable, Credit Loss, Expense (Reversal)USD | — | — | — | — | — | — | — | — | — | — | 0Source | 54,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 8,601,000Source | 12,833,000Source | 14,915,000Source | 15,328,000Source | 15,248,000Source | 7,543,000Source | 70,387,000Source | 59,345,000Source | 70,143,000Source | 138,590,000Source |
| Cost of RevenueUSD | — | — | 2,465,000Source | 4,317,000Source | 3,512,000Source | 2,098,000Source | 2,064,000Source | 2,732,000Source | 9,338,000Source | 16,288,000Source | 12,809,000Source | 38,033,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 11,217,000Source | 13,568,000Source | 10,927,000Source | 12,317,000Source | 9,779,000Source | 12,355,000Source | 47,074,000Source | 55,148,000Source | 53,250,000Source | 52,172,000Source |
| Operating Income (Loss)USD | — | — | -18,949,000Source | -16,557,000Source | -11,229,000Source | -12,862,000Source | -8,043,000Source | -20,486,000Source | -41,739,000Source | -58,519,000Source | -68,069,000Source | -34,881,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -1,292,000Source | -4,922,000Source | -1,301,000Source | -984,000Source | -1,290,000Source | -942,000Source | -4,813,000Source | -10,393,000Source | -12,274,000Source | 124,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -19,607,000Source | -20,630,000Source | -11,995,000Source | -13,262,000Source | -8,668,000Source | -20,677,000Source | -43,927,000Source | -65,242,000Source | -76,171,000Source | -33,316,000Source |
| Income Tax Expense (Benefit)USD | — | — | 8,000Source | 10,000Source | 10,000Source | 10,000Source | 36,000Source | 11,000Source | 47,000Source | 34,000Source | 69,000Source | 276,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -19,615,000Source | -20,640,000Source | -12,005,000Source | -13,272,000Source | -8,704,000Source | -20,688,000Source | -43,974,000Source | -65,276,000Source | -76,240,000Source | -33,592,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.22Source | -0.29Source | -0.13Source | -0.16Source | -0.1Source | -0.25Source | -0.5Source | -0.89Source | -1.12Source | -0.51Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.22Source | -0.29Source | -0.13Source | -0.16Source | -0.1Source | -0.25Source | -0.5Source | -0.89Source | -1.12Source | -0.51Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 90,251,000Source | 72,032,000Source | 91,053,000Source | 85,389,000Source | 90,768,000Source | 82,410,000Source | 87,142,000Source | 73,408,000Source | 68,131,000Source | 65,344,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 90,251,000Source | 72,032,000Source | 91,053,000Source | 85,389,000Source | 90,768,000Source | 82,410,000Source | 87,142,000Source | 73,408,000Source | 68,131,000Source | 65,344,000Source |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 27,550,000Source | 29,390,000Source | 26,144,000Source | 28,190,000Source | 23,291,000Source | 28,029,000Source | 112,126,000Source | 117,864,000Source | 138,212,000Source | 173,471,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 50,000Source | 36,000Source | 69,000Source | 283,000Source |
| Debt and Equity Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | — | 208,000Source |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | — | — | — | 3,900,000Source | — | — | — | — | 300,000Source | 6,902,000Source | 12,215,000Source | — |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | 0Source | 778,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -43,908,000Source | -65,231,000Source | -76,169,000Source | -33,269,000Source |
| Investment Income, InterestUSD | — | — | 634,000Source | 849,000Source | 535,000Source | 584,000Source | 665,000Source | 751,000Source | 2,625,000Source | 3,670,000Source | 4,172,000Source | 1,441,000Source |
| Research and Development ExpenseUSD | — | — | 13,868,000Source | 11,505,000Source | 11,705,000Source | 13,775,000Source | 11,448,000Source | 12,942,000Source | 52,307,000Source | 46,263,000Source | 58,885,000Source | 80,099,000Source |
Filing attachments
d189706dex991.htm · 8-K · 2026-11-12
Exhibit 99.1 Codexis, Inc. 200 Penobscot Drive Redwood City, CA 94063 +1 (650) 421-8100 codexis.com Codexis Reports Third Quarter 2026 Financial Results and Provides Business Update Reports revenue of $19.3 million for the third quarter of 2026, company reiterates full-year revenue guidance Shared new advances in RNA therapeutic manufacturing at TIDES Europe Entered into a $60 million term loan facility with Trinity Capital; initial tranche used to refinance current debt …
Read attachment ↗d187712dex41.htm · 8-K · 2026-11-10
Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.5 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. WARRANT TO PURCHASE ST…
Read attachment ↗d171403dex991.htm · 8-K · 2026-08-11
EX-99.1 2 d171403dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Codexis Reports Second Quarter 2026 Financial Results Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis ® Manufacturing Platform exerts enzyme-driven stereoisomer control of siRNA Completed successful equity capital raise of approximately $25 million in net proceeds REDWOOD…
Read attachment ↗d112205dex991.htm · 8-K · 2026-05-07
EX-99.1 2 d112205dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Codexis Reports First Quarter 2026 Financial Results Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis manufacturing platform capabilities REDWOOD CITY, Calif., May 7, 2026 - Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturi…
Read attachment ↗ex99-1.htm · SCHEDULE 13G/A · 2026-05-05
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of May 05, 2026, is by and among Opaleye Management Inc., Opaleye, L.P. and James Silverman (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G with respect to common shares of Codexis, Inc. beneficially owned by them from time to time. Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated und…
Read attachment ↗d106216dex991.htm · 8-K · 2026-03-11
EX-99.1 2 d106216dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway through 2027 Completed $37.8 million Technology Transfer Agreement with Merck REDWOOD CITY, Calif., March 11, 2026 - Codexis, Inc. (NASDAQ: CDXS), a leading provider of…
Read attachment ↗